Alentis Therapeutics AG

https://www.alentis.ch

Alentis Therapeutics is a Swiss-based biotech that focuses on developing breakthrough treatments for fibrotic diseases. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). The Company’s lead candidates are monoclonal antibodies that are highly selective for Claudin-1, a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of liver fibrosis and fibrosis-driven hepatobiliary cancers. It also has early discovery programs exploring the potential of Claudin-1 inhibition in the treatment of fibrosis of other tissues including the kidney and lung. These represent very large and expanding markets with high unmet need. Furthermore, the company uses a patient-derived drug and target discovery platform to develop medicines for advanced fibrosis. Unlike current therapies in fibrosis, which mostly address the disease indirectly, Alentis’ pioneering approach has the potential to directly modify and reverse the course of disease progression. Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. *

	Start	2019-03-29 established
	Industry	drug development
	Industry 2	antifibrotic
	Person	Iacone, Roberto (Alentis Therapeutics 202007– CEO before Versant Ventures + Roche)
	Person 2	Tordjman, Rafaèle (Jeito Capital 201806– President + Founder before Sofinnova Partners 2001–2017)

	Region	Basel BS
	Country	Switzerland
	Street	60c Hochbergerstr.
	City	4057 Basel BS
	Tel	+41-61-638-2338
		Address record changed: 2022-10-29

Basic data	Employees	A: 1 to 10 (2022-01-01)

		* Document for »About Section«: Alentis Therapeutics AG. (6/15/21). "Press Release: Alentis Therapeutics Raises USD 67 Million in Series B Financing". Basel & Strasbourg.

		Record changed: 2025-03-16